<DOC>
	<DOCNO>NCT02724202</DOCNO>
	<brief_summary>The purpose study test safety find response rate combine dietary supplement , curcumin , standard care , FDA-approved chemotherapy drug 5-fluorouracil ( 5FU , Adracil ) see effect ( good bad ) combine treatment colon cancer .</brief_summary>
	<brief_title>Curcumin Combination With 5FU Colon Cancer</brief_title>
	<detailed_description>Confirm clinical safety identify clinical response rate combination treatment curcumin 5FU chemorefractory CRC patient . To determine whether curcumin administration induces systemic alteration inflammatory epigenetic biomarkers patient chemoresistant metastatic colorectal cancer ( CRC ) . To correlate altered biomarker finding clinical response accord RECIST V1.1 survival criterion .</detailed_description>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Curcumin</mesh_term>
	<criteria>Male female 18 year old , time signing informed consent . Capable give write informed consent , include compliance requirement restriction list consent form . Histologically cytologically confirm diagnosis metastatic colorectal cancer response standard 5FU base therapy . Performance Status ( PS ) score 0 2 accord Eastern Cooperative Oncology Group ( ECOG ) scale . Able swallow retain oral medication . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea ( questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 miliinternation unit ( MIU ) /ml estradiol &lt; 40 pg/ml ( 140pmol/L ) confirmatory Childbearing potential agrees use contraception method abstinence , intrauterine device ( IUD ) , barrier method birth control pills prior start dose sufficiently minimize risk pregnancy point three month last dose study medication . Male subject must agree use method contraception . This criterion must follow time first dose study medication three month last dose study medication . Adequate organ system function define follow : System Laboratory Values Hematologic Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L Hemoglobin ≥ 9.5 g/dL Platelets ≥ 75 x 10^9/L For subject warfarinbased anticoagulant : Prothrombin time/International normalize ratio ( PT/INR ) partial thromboplastin time ( PTT ) ≤ 1.1x upper limit normal ( ULN ) INR ( subject warfarinbased anticoagulant ) : 23 x ULN Hepatic Total bilirubin ≤ 1.5x ULN ( isolated bilirubin &gt; 1.5x ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) Aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) 1 ≤ 1.5x ULN Albumin ≥ 2.5 g/dL Renal Creatinine ≤ ULN ; Calculated creatinine clearance2 ≥ 50 mL/min ; Metabolic Fasting Serum Glucose &lt; 250 mg/dL Cardiac Left Ventricular Ejection fraction ( LVEF ) ≥ low limit normal ( LLN ) echocardiogram ( ECHO ) Blood pressure Systolic &lt; 160 mm Hg Diastolic &lt; 100 mm Hg . 1 . If liver metastasis present , AST ALT ≤ 2.5x ULN permit 2 . As calculated CockcroftGault formula . Chemotherapy , radiotherapy , immunotherapy , anticancer therapy include investigational drug within 28 day 5 halflives , whichever short prior first dose one investigational drug describe study . Unresolved toxicity National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events , Version 4.0 ( NCICTCAE V4 ) &gt; Grade 1 previous anticancer therapy . Presence active GI disease condition could affect gastrointestinal absorption ( malabsorption syndrome ) predispose subject GI ulceration . Evidence mucosal internal bleeding Any major surgery within last four week Uncontrolled diabetes mellitus Any malignancy relate human immunodeficiency virus ( HIV ) , know history HIV , history know Hepatitis B virus ( HBV ) surface antigen positivity ( subject document laboratory evidence HBV clearance may enrol ) positive Hepatitis C virus ( HCV ) antibody . Known active infection require parenteral oral antiinfective treatment . Subjects brain metastasis exclude brain metastasis : Symptomatic Treated ( surgery , radiation therapy ) clinically radiographically stable one month therapy ( assess least 2 distinct contrast enhance MRI CT scan least one month period ) , Asymptomatic untreated &gt; 1 cm long dimension History evidence current clinically significant uncontrolled arrhythmia . Subjects control atrial fibrillation &gt; 1 month prior study Day 1 eligible . History acute coronary syndrome ( include unstable angina ) , myocardial infarction , coronary angioplasty , stenting bypass graft within six month screen . Class II , III , IV heart failure define New York Heart Association ( NYHA ) functional classification system . Any serious unstable preexist medical , psychiatric , condition ( include lab abnormality ) could interfere subject 's safety providing informed consent . Known immediate delay hypersensitivity component study treatment ( ) . Evidence severe uncontrolled systemic disease ( unstable uncompensated respiratory , hepatic , renal , cardiac disease , include unstable hypertension ) . Pregnant lactating female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Curcumin</keyword>
	<keyword>5FU</keyword>
	<keyword>5-fluorouracil</keyword>
	<keyword>Adracil</keyword>
	<keyword>5FU Resistant</keyword>
	<keyword>Metastatic Colon Cancer</keyword>
	<keyword>Colon Cancer</keyword>
</DOC>